Search
19/08/2024
'Gout was like the boss'. A qualitative study exploring the impact of gout on employment
Diaz-Torne, C, Pou, MA, Horne, A, Gasteiger, C, Dalbeth, N. 'Gout was like the boss'. A qualitative study exploring the impact of gout on employment. RMD Open. 2024; 10(3)DOI:10.1136/rmdopen-2024-004443. PMID:39160089. IF:4.700(Q1/1D).
01/04/2024
Application of the 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease in a seronegative rheumatoid arthritis cohort
Codes-Méndez, H, Sainz, L, Park, HS, Corominas, H, Diaz-Torne, C. Application of the 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease in a seronegative rheumatoid arthritis cohort. RMD Open. 2024; 10(2)DOI:10.1136/rmdopen-2024-004173. PMID:38626930. IF:4.700(Q1/1D).
01/08/2024
Diagnosed and undiagnosed cough-related stress urinary incontinence in women with refractory or unexplained chronic cough: Its impact on general health status and quality of life
Arismendi, E, Puente-Maestu, L, Domingo, C, Dávila, I, Quirce, S, González-Barcala, FJ, Crespo-Lessmann, A, Sánchez-Jareño, M, Rivas-Pardinas, C, Cea-Calvo, L. Diagnosed and undiagnosed cough-related stress urinary incontinence in women with refractory or unexplained chronic cough: Its impact on general health status and quality of life. Chronic Respiratory Disease. 2024; 21DOI:10.1177/14799731241273751. PMID:39222070. IF:2.300(Q2/5D).
01/05/2026
Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial
Behrens, GMN, Assoumou, L, Liegeon, G, Antinori, A, Micán, R, Genderini, FG, Post, FA, Rockstroh, JK, Hamzah, L, Domingo, P, Curran, A, Laguno, M, Fletcher, C, Moody, J, Pozniak, A. Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial. LANCET INFECTIOUS DISEASES. 2026; 26(5)DOI:10.1016/S1473-3099(25)00681-4. PMID:41344354. IF:31.000(Q1/1D).
04/03/2026
Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial
Català-Moll, F, Blázquez-Bondia, C, Farré-Badia, J, Torres, F, Manzardo, C, Bonfill, E, Curran, A, Domingo, P, Podzamczer, D, Force, L, Falcó, V, Parera, M, Casadellà, M, Miró, JM, Noguera-Julian, M, Paredes, R. Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial. Nature Communications. 2026; 17(1)DOI:10.1038/s41467-026-69846-7. PMID:41781390. IF:15.700(Q1/1D).
28/03/2024
Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudine
de Lazzari, E, Negredo, EB, Domingo, P, Tiraboschi, JM, Ribera, E, Abdulghani, N, Alba, V, Fernández-Arroyo, S, Viladés, C, Peraire, J, Gatell, JM, Blanco, JL, Vidal, F, Rull, A, Martinez, E. Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudine. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2024; 79(5)DOI:10.1093/jac/dkae083. PMID:38546974. IF:3.600(Q2/3D).
28/03/2024
Evolving AIDS- and non-AIDS Mortality and Predictors in the PISCIS Cohort of People Living With HIV in Catalonia and the Balearic Islands (Spain), 1998-2020
Nomah, DK, Jamarkattel, S, Bruguera, A, Moreno-Fornés, S, Díaz, Y, Alonso, L, Aceitón, J, Llibre, JM, Domingo, P, Saumoy, M, Homar, F, Fanjul, F, Navarro, J, de la Mora, L, Knobel, H, Orti, A, Martin-Iguacel, R, Miró, JM, Casabona, J, Reyes-Urueña, J. Evolving AIDS- and non-AIDS Mortality and Predictors in the PISCIS Cohort of People Living With HIV in Catalonia and the Balearic Islands (Spain), 1998-2020. Open Forum Infectious Diseases. 2024; 11(4)DOI:10.1093/ofid/ofae132. PMID:38560603. IF:3.800(Q1/3D).
01/01/2024
Medical oncology workload, workforce census, and needs in Spain: two nationwide studies by the Spanish Society of medical oncology
Fernandez Montes A., Elez E., de la Haba-Rodriguez J., Paez D., Mendez-Vidal M.J., Felip E., Rodriguez-Lescure A.. Medical oncology workload, workforce census, and needs in Spain: two nationwide studies by the Spanish Society of medical oncology. Clinical & Translational Oncology. 2024; 26DOI:10.1007/s12094-023-03225-2. PMID:37316754. IF:2.500(Q3/6D).